8205 El Rio Street
About InGeneronFounded in 2006, InGeneron is a privately held company, developing its own products for multiple markets and expanding its reach through licensing agreements. The company was formed to innovate cell-based technologies for healthcare and life science research.
CEO: Michael Coleman
CFO: Fabian Alt
11 articles with InGeneron
FDA-Approved Randomized Controlled Feasibility Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function Over Corticosteroid Injection to Address Symptomatic Partial-Thickness Rotator Cuff Tears
InGeneron announces publication of favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.
InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure
Animal model for the study of Chronic Myocardial Infarction indicates, for the first time, regenerative potential in a pig’s heart using uncultured autologous adipose-derived regenerative cells prepared at point of care.
InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic
Company raises up to additional $23 million from strategic partner Sanford Health to advance pivotal program in rotator cuff tendinopathy
Company enrolls first patients in multi-center trial evaluating regenerative cell therapy at the point of care for partial rotator cuff tears
Company enrolls first patients in feasibility studies for chronic back pain and wrist osteoarthritis, setting clinical development focus on orthopedic indications
InGeneron Announces Publication Of Positive Results From Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology
InGeneron Announces Presentation Of Results From Investigator Initiated Case Series Of Its Regenerative Cell Therapy In Chronic Back Pain At IFATS